Burden of Rotavirus Gastroenteritis in the Pediatric Population in Central and Eastern Europe: Serotype Distribution and Burden of Illness
Overview
Affiliations
Background: Rotaviral gastroenteritis (RVGE) is the leading cause of severe diarrhea in children under five years of age worldwide. This comprehensive review aims to estimate the burden of RVGE among children in Central and Eastern Europe.
Methods: An extensive search of the biomedical literature (1999-2009) was conducted in major databases. Studies pertaining to the epidemiology and burden of rotavirus in Central and Eastern Europe were captured and data from each country was systematically extracted and compared.
Results: This literature search captured 38 studies pertaining to RVGE infection in the region. Among children under 15 years of age, RVGE accounted for between 22.0% and 55.3% of all cases of acute gastroenteritis per year. For most countries RVGE was most common in the winter months, although it was reported year round in Bulgaria. Geographical comparison of genotyping data revealed that three genotype combinations, G1P[8], G4P[8], and G2P[4] were present in all countries for which full genotyping data was available. Genotype predominance varied on a season to season basis within each country. Only limited data was available for healthcare resource utilization, and economic burden for this region.
Conclusions: RVGE is a common disease associated with significant morbidity, and mortality. While three genotype combinations currently predominate in the region, the dominance of a certain serotype can change dramatically from year to year and from country to country. A vaccination program with broad serotype coverage may help to decrease the burden of RVGE in Central and Eastern Europe.
Acute Infectious Gastroenteritis in Infancy and Childhood.
Posovszky C, Buderus S, Classen M, Lawrenz B, Keller K, Koletzko S Dtsch Arztebl Int. 2020; 117(37):615-624.
PMID: 33263539 PMC: 7805585. DOI: 10.3238/arztebl.2020.0615.
Tafalla M, Gardovska D, Gopala K, Kozlovska L Hum Vaccin Immunother. 2018; 15(6):1272-1278.
PMID: 30335570 PMC: 6663140. DOI: 10.1080/21645515.2018.1534515.
Tiholova M, Gopala K, Berberova M, Strokova-Stoilova M, Tafalla M Germs. 2016; 6(3):97-105.
PMID: 27622162 PMC: 5018391. DOI: 10.11599/germs.2016.1095.
Nosocomial rotavirus infection: An up to date evaluation of European studies.
Gervasi G, Capanna A, Mita V, Zaratti L, Franco E Hum Vaccin Immunother. 2016; 12(9):2413-8.
PMID: 27185183 PMC: 5027725. DOI: 10.1080/21645515.2016.1183858.
The cost effectiveness of rotavirus vaccination in Iran.
Mousavi Jarrahi Y, Zahraei S, Sadigh N, Esmaeelpoor Langeroudy K, Khodadost M, Ranjbaran M Hum Vaccin Immunother. 2015; 12(3):794-800.
PMID: 26360331 PMC: 4964645. DOI: 10.1080/21645515.2015.1087626.